Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459346 | 0.96 | ALDH1A1 (0.34) | MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL23459103 | 0.92 | KMT2A (0.31) | MEN1ALDH1A1KMT2A | |
| SCHEMBL25338490 | 0.82 | MEN1 (0.30) | MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL2769762 | 0.76 | CNR2 (0.37) | ALDH1A1 | |
| SCHEMBL29043368 | 0.76 | HCRTR2 (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL8182036 | 0.76 | LMNA (0.43) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2770951 | 0.75 | USP2 (0.48) | ALDH1A1 | |
| SCHEMBL23477736 | 0.73 | HCRTR2 (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL99571 | 0.72 | CNR2 (0.40) | ALDH1A1 | |
| SCHEMBL3963090 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211122-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019236-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | MEN1 3734/4885ALDH1A1 3671/4885POLB 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.